主题：主要泌尿外科癌症手术后出院时无阿片类药物处方策略的实施和评估。
Re: Implementation and Assessment of No Opioid Prescription Strategy at Discharge After Major Urologic Cancer Surgery.
机构信息
Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Division of Urology, University of Texas Medical Branch, Galveston, TX, USA.
出版信息
Eur Urol. 2023 Jul;84(1):139-140. doi: 10.1016/j.eururo.2023.03.012. Epub 2023 Mar 24.
The authors prospectively evaluated the implementation of a prespecified protocol to eliminate post-discharge opioid prescription after major urologic cancer surgery at a single center among a predominantly opioid naïve population. The intervention included both provider and patient education along with a standardized regimen for non-opioid analgesia during the inpatient stay and after discharge. Use of a standardized protocol nearly eliminated opioid prescriptions after major urologic cancer surgery without adversely impacting patient reported pain control and satisfaction, unplanned visits, and complications.
作者前瞻性地评估了在一个以阿片类药物初治为主的单一中心，实施一项预先指定的方案以消除大泌尿外科癌症手术后出院后阿片类药物处方的情况。该干预措施包括对医护人员和患者进行教育，以及在住院期间和出院后使用标准化的非阿片类镇痛药方案。使用标准化方案几乎消除了大泌尿外科癌症手术后的阿片类药物处方，而不会对患者报告的疼痛控制和满意度、计划外就诊和并发症产生不利影响。
Zotero 插件